Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
MacroGenics (MGNX)
NASDAQ:MGNX
Holding MGNX?
Track your performance easily
MGNX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.95 - $21.88
Previous Close$3.21
Volume463.17K
Average Volume (3M)655.05K
Market Cap
$201.47M
Enterprise Value$55.95M
Total Cash (Recent Filing)$179.63M
Total Debt (Recent Filing)$34.10M
Price to Earnings (P/E)―
Beta1.21
Next Earnings
Mar 04, 2025EPS Estimate
-$0.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.57
Shares Outstanding62,763,448
10 Day Avg. Volume685,360
30 Day Avg. Volume655,054
Standard Deviation0.31
R-Squared0.12
Alpha0.00288
Financial Highlights & Ratios
Price to Book (P/B)1.72
Price to Sales (P/S)1.56
Price to Cash Flow (P/CF)0.90
P/FCF Ratio0.90
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.40
Enterprise Value/Gross Profit1.14
Enterprise Value/Ebitda-0.64
Forecast
1Y Price Target
$6.00Price Target Upside85.19% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
MacroGenics News
PremiumCompany Announcements
MacroGenics Announces Leadership Transition in Financial Roles
PremiumCompany Announcements
MacroGenics Inc. Reports Strong Revenue Growth
PremiumPre-Earnings
Is MGNX a Buy, Before Earnings?Bulls Say, Bears Say
Bulls Say
Financial StabilityMGNX ended 3Q24 with $200.4M in cash and equivalents, with a cash runway into 2026, inclusive of projected and anticipated future payments from partners and product revenues.
Oncology Research PotentialOptimism remains about the potential of B7-H3 as a promising oncology target, focusing on the company's second B7-H3 ADC program, MGC026, which is expected to have initial clinical data disclosed in 2025.
Strategic Financial MoveThe sale of global rights to Margenza to TerSera Therapeutics for $40M upfront is viewed positively as it provides non-dilutive financing and allows the company to focus on its pipeline efforts.
Bears Say
Financial PerformanceThe company's reported net loss of $0.89 per share is wider than anticipated, indicating deeper financial challenges.
Pipeline DevelopmentThe company is facing a holding pattern in its pipeline development, having paused all efforts related to vobra duo, including the lorigerlimab combo, and sold Margenza.
Safety ConcernsSafety concerns have intensified with vobra duo, as the safety profile deteriorated, leading to increased treatment-related fatalities and adverse events.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
MGNX FAQ
What was MacroGenics’s price range in the past 12 months?
MacroGenics lowest stock price was $2.95 and its highest was $21.88 in the past 12 months.
What is MacroGenics’s market cap?
Currently, no data Available
When is MacroGenics’s upcoming earnings report date?
MacroGenics’s upcoming earnings report date is Mar 04, 2025 which is in 101 days.
How were MacroGenics’s earnings last quarter?
MacroGenics released its earnings results on Nov 05, 2024. The company reported $0.9 earnings per share for the quarter, beating the consensus estimate of $0.212 by $0.688.
Is MacroGenics overvalued?
According to Wall Street analysts MacroGenics’s price is currently Undervalued.
Does MacroGenics pay dividends?
MacroGenics does not currently pay dividends.
What is MacroGenics’s EPS estimate?
MacroGenics’s EPS estimate is -$0.4.
How many shares outstanding does MacroGenics have?
MacroGenics has 62,763,447 shares outstanding.
What happened to MacroGenics’s price movement after its last earnings report?
MacroGenics reported an EPS of $0.9 in its last earnings report, beating expectations of $0.212. Following the earnings report the stock price went up 11.141%.
Which hedge fund is a major shareholder of MacroGenics?
Among the largest hedge funds holding MacroGenics’s share is Woodline Partners LP. It holds MacroGenics’s shares valued at 621K.
---
MacroGenics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.00 (85.19% Upside)
$6.00 (85.19% Upside)
Blogger Sentiment
Bullish
MGNX Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 2.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 9.3%
Last 30 Days ▼ 9.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-56.68%
12-Months-Change
Fundamentals
Return on Equity
-62.17%
Trailing 12-Months
Asset Growth
-22.20%
Trailing 12-Months
Company Description
MacroGenics
MacroGenics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. 2. Its product pipeline includes Margetuximab, Flotetuzumab, Enoblituzumab, MGA012, MGD013, MGD019, MGD009, MGC018, and MGD007 for oncology; and MGD014 for infectious diseases. The company was founded by Scott E. Koenig, Jeffrey V. Ravetch, LeRoy E. Hood, Ruedi Aebersold, and Alan Aderem on August 14, 2000 and is headquartered in Rockville, MD.
---
MGNX Earnings Call
Q3 2024
0:00 / 0:00
---
MGNX Stock 12 Month Forecast
Average Price Target
$6.00
▲(85.19% Upside)
Technical Analysis
Best Analysts Covering MGNX
1 Year
1 Year Success Rate
8/28 ratings generated profit
1 Year Average Return
-15.43%
reiterated a buy rating 17 days ago
Copying Jonathan Chang's trades and holding each position for 1 Year would result in 28.57% of your transactions generating a profit, with an average return of -15.43% per trade.
---